Abstract:Radiotherapy is one of the major treatment methods for patients with non-small cell lung cancer (NSCLC). However the presence of radio-resistant cancer stem cells (CSC) may attribute to the relapse or poor outcome of radiotherapy. We previously identified calcium channel α2δ1 subunit (CACNA2D1) isoform 5 as a marker for CSC in hepatocellular carcinoma. This study aimed to investigate the radio-sensitivity of CACNA2D1+ cells in NSCLC cell lines. NSCLC cell lines A549, H1975 and PC9 were used. CACNA2D1-knockdown or overexpression cell lines were established by lentivirus infection. The proportion of CACNA2D1+ cells before and after radiation was analyzed by flow cytometry. Colony formation assay was performed to determine the radiosensitivity. Sphere formation assay in serum-free medium was performed to evaluate the self-renewal capacity. γH2AX foci were analyzed by immunofluorescence. The monoclonal antibody of CACNA2D1 was applied alone or combined with radiation to CACNA2D1+ cells and colony formation and sphere formation assays were performed to determine its effect on CACNA2D1+ cells. CACNA2D1+ cells had higher sphere-forming efficiency, and were resistant to radiation compared with CACNA2D1- cells. In unsorted cells the CACNA2D1+ percentage was enhanced after radiation. These data suggest CACNA2D1+ NSCLC cells are relatively radio-resistant. Knockdown of CACNA2D1 in CACNA2D1-high A549 enhanced radiosensitivity, while overexpression of CACNA2D1 in CACNA2D1-low PC9 and H1975 reduced radiosensitivity, suggesting CACNA2D1 converts the radio-resistance. The number of γH2AX foci increased after radiation, and decreased more rapidly in CACNA2D1-overexpression cells than control group. Moreover, in CACNA2D1-overexpression cells, the baseline phosphorylation level of CHK2 and ATM was higher than control group, and were more activated after radiation, suggesting CACNA2D1 overexpression resulted in an increase in the DNA damage repair capacity. The monoclonal antibody of CACNA2D1 had a synergetic effect with radiation to block self-renewal of CACNA2D1+ A549 cells. The antibody also enhanced radiosensitivity in CACNA2D1+ cells in colony formation assay. CACNA2D1 marks radio-resistant cancer stem-like cells in NSCLC. CACNA2D1 converts resistance to radiation, partially by enhancing the DNA damage repair efficiency. The monoclonal antibody of CANCA2D1 enhances the radio-sensitivity of CACNA2D1+ cells, suggesting its potential to improve the treatment outcome when combined with radiation on NSCLC.

Cacna2d3 Enhances The Chemosensitivity Of Esophageal Squamous Cell Carcinoma To Cisplatin Via Inducing Ca2+-Mediated Apoptosis And Suppressing Pi3k/Akt Pathways

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Dasatinib Enhances Cisplatin Sensitivity in Human Esophageal Squamous Cell Carcinoma (ESCC) Cells Via Suppression of PI3K/AKT and Stat3 Pathways

Down-Regulation of CIDEA Promoted Tumor Growth and Contributed to Cisplatin Resistance by Regulating the JNK-p21/Bad Signaling Pathways in Esophageal Squamous Cell Carcinoma

Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

P2.05-002 CACNA2D1 Enhances Radio-Resistance in Cancer Stem-Like Cells in NSCLC

Genome-scale CRISPR Activation Screening Identifies a Role of ELAVL2-CDKN1A Axis in Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma.

Vitamin D Promotes the Cisplatin Sensitivity of Oral Squamous Cell Carcinoma by Inhibiting LCN2-modulated NF-κB Pathway Activation Through RPS3.

Investigation of Tumor Suppressing Function of CACNA2D3 in Esophageal Squamous Cell Carcinoma

Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma

Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer

Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin.

miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway

CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal squamous cell carcinomas

Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis

CACNA1H restrains chemotherapy resistance in ovarian clear cell carcinoma cells by repressing autophagy

Entinostat Reverses Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Via Down-Regulation of Multidrug Resistance Gene 1.

CDK-associated Cullin 1 Can Promote Cell Proliferation and Inhibit Cisplatin-Induced Apoptosis in the AGS Gastric Cancer Cell Line

Targeting the mitochondrial calcium uniporter inhibits cancer progression and alleviates cisplatin resistance in esophageal squamous cell carcinoma

MicroRNA-125a-5p Enhances the Sensitivity of Esophageal Squamous Cell Carcinoma Cells to Cisplatin by Suppressing the Activation of the STAT3 Signaling Pathway

TNF‑α‑mediated Upregulation of SOD‑2 Contributes to Cell Proliferation and Cisplatin Resistance in Esophageal Squamous Cell Carcinoma.